Perioperative management of patients on new oral anticoagulants

British Journal of Surgery

Volumn 101, Issue 7, 2014, Pages 742-749

  Lai, A ^a   Davidson, N ^b   Galloway, S W ^b   Thachil, J ^c  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; DRUG DERIVATIVE; EDOXABAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; WARFARIN;

BIOAVAILABILITY; BLEEDING; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DRUG MONITORING; ELECTIVE SURGERY; EMERGENCY; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HUMAN; MEDICATION COMPLIANCE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; REVIEW; TIME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; EMERGENCIES; HALF-LIFE; HEMORRHAGE; HUMANS; MEDICATION ADHERENCE; MORPHOLINES; PREOPERATIVE CARE; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; SURGICAL PROCEDURES, ELECTIVE; THIAZOLES; THIOPHENES; TIME FACTORS; WARFARIN;

EID: 84900501828     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9485     Document Type: Review

References (33)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
2. National Institute for Health and Care Excellence (NICE). Stroke and systemic embolism (prevention, non-valvular atrial fibrillation)-apixaban. Technology appraisal TA275. http://www.nice.org.uk/guidance/index.jsp?action= byID&o=14086 [accessed 19 February 2013].
3. National Institute for Health and Care Excellence (NICE). Atrial fibrillation (stroke prevention)-rivaroxaban. Technology appraisal TA256. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=13746 [accessed 19 February 2013].
4. National Institute for Health and Care Excellence (NICE). Atrial fibrillation-dabigatran etexilate. Technology appraisal TA249. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=13677 [accessed 19 February 2013].
5. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-2106.
6. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.,; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109: 596-605.
11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
12. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
13. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al.; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
14. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A,. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
15. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
16. Barrett YC, Wang Z, Frost C, Shenker A,. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
17. Tripodi A., Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost 2011; 105: 735-736.
18. Baglin T., The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11 (Suppl 1): 122-128.
19. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W,. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-2391.
20. Siegal DM, Crowther MA,. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013; 34: 489-498b.
21. Kaatz S, Crowther M,. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 2013; 36: 195-202.
22. Tsiara S, Pappas K, Boutsis D, Laffan M,. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol 2011; 52: 52-67.
23. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
24. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-676.
25. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
26. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-S145.
27. Crowther MA, Warkentin TE,. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 7 (Suppl 1): 107-110.
28. Spyropoulos AC, Douketis JD,. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954-2962.
29. Eriksson BI, Quinlan DJ, Eikelboom JW,. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
30. Quinlan DJ, Eriksson BI,. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Best Pract Res Clin Haemat 2013; 26: 171-182.
31. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P,; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
32. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
33. Werth S, Halbritter K, Beyer-Westendorf J,. Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Ther Clin Risk Manag 2012; 8: 139-147.